Why do people with obesity, but without diabetes, start taking semaglutide?

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

Little-known startup, backed by Foresite and Samsara, swings $60M China I&I deal

A new, still-in-stealth biotech is paying eight figures to acquire the rights to an experimental I&I drug out of China. Vignette Bio — a company

September 5, 2024

Undervalued pharmaceutical stock Cybin emerges as market pioneer – Biotech Investments

EQS Newswire / 31/10/2023 / 21:41 EST/EDT Undervalued pharmaceutical stock Cybin emerges as market pioneer The stock market, being a zero-sum game, often presents

November 2, 2023

M&A revival with a 71% increase in billion-dollar transactions in Q1 2024

Figure 1: M&A deal volume and value globally from 2021 to Q1 2024. Credit: GlobalData. Mergers and acquisitions (M&As) in the biopharmaceutical industry involving companies

May 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.